Skip to main content
. 2020 Jul 9;35(1):1–17. doi: 10.1038/s41375-020-0954-2

Fig. 4. Symptom response.

Fig. 4

Individual changes in MFSAF total symptom score (TSS) at the end of treatment cycle 6 in JAKARTA with (a) placebo and (b) fedratinib 400 mg/day; [34] and in JAKARTA2 with fedratinib 400 mg/day (c) in patients previously treated with ruxolitinib [71].